Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 2828-year-old man is admitted to the intensive care unit with diabetic ketoacidosis. He is initially started on a continuous intravenous regular insulin infusion and 0.9%0.9\% normal saline. Over the next several hours, his blood glucose decreases from 550550 mg/dL to 220220 mg/dL. However, his calculated anion gap remains elevated at 1818 mEq/L, and his serum bicarbonate is 1414 mEq/L. He is clinically stable, and his mental status is improving.

Arrange the following subsequent management and monitoring steps in the correct chronological order to safely resolve the ketoacidosis and transition his therapy.

  1. 1Add 5%5\% dextrose to the intravenous fluids while maintaining the continuous insulin infusion.
  2. 2Confirm the closure of the anion gap and the normalization of serum bicarbonate.
  3. 3Administer the first dose of long-acting subcutaneous basal insulin.
  4. 4Maintain the continuous intravenous insulin infusion for a 11- to 22-hour overlap period.
  5. 5Discontinue the continuous intravenous regular insulin infusion.

Cevap

The correct sequence is to first add dextrose to the IV fluids, then verify resolution of the anion gap, administer subcutaneous insulin, maintain a 11- to 22-hour overlap with the IV insulin, and finally discontinue the IV insulin.
The chronological management of diabetic ketoacidosis (DKA) focuses first on clearing ketoacids, which requires continuous insulin. When glucose falls below 200200-250250 mg/dL but the anion gap remains elevated, dextrose must be added to the IV fluids so insulin can be continued without causing hypoglycemia. Once the anion gap closes (≤12\leq 12 mEq/L), DKA is considered resolved. At this point, if the patient can tolerate oral intake, subcutaneous insulin is administered. Because IV insulin has a half-life of only a few minutes and subcutaneous insulin requires 11-22 hours for systemic absorption, the IV infusion must be continued for a 11- to 22-hour overlap period. Only after this overlap can the IV insulin be safely discontinued. Failing to overlap correctly is a major cause of rebound DKA in the hospital setting.

Adım Adım Çözüm

1
Evaluate the current metabolic parameters and adjust intravenous fluids.
Recognize that blood glucose has dropped below 250250 mg/dL but ketoacidosis persists (anion gap >12> 12 mEq/L). Dextrose is added to the IV fluids to prevent hypoglycemia while maintaining the insulin drip.
Continuous insulin is required to halt lipolysis and clear ketones; it cannot be stopped or significantly decreased based solely on glucose levels.
2
Monitor serial laboratory values until metabolic resolution is achieved.
Confirm that the anion gap has closed (≤12\leq 12 mEq/L) and bicarbonate has normalized (≥15\geq 15 mEq/L).
This indicates the underlying ketoacidosis has resolved, allowing for the safe transition to maintenance therapy.
3
Initiate the transition to subcutaneous insulin.
Administer a dose of long-acting subcutaneous basal insulin.
Subcutaneous insulin must be on board before the IV insulin is withdrawn to maintain basal metabolic control.
4
Overlap therapies to ensure continuous insulin coverage.
Continue the IV regular insulin infusion for 11 to 22 hours after the subcutaneous injection.
Subcutaneous insulin has a delayed onset of action. An overlap prevents a period of absolute insulin deficiency that could trigger rebound ketoacidosis.
5
Finalize the transition.
Discontinue the IV regular insulin infusion.
The subcutaneous insulin has now reached therapeutic levels, providing safe and continuous coverage.

Anahtar Kavram

Successful management of diabetic ketoacidosis requires maintaining an insulin infusion until the anion gap closes (adding dextrose if glucose falls prematurely) and ensuring a 11- to 22-hour overlap when transitioning to subcutaneous insulin to prevent rebound ketoacidosis.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru